Nirav S. Jhaveri
CIK 2011481 · Chief Financial Officer · last filed 2026-10-05
Nirav S. Jhaveri is a Chief Financial Officer who has filed 6 SEC Form 4 insider transactions across 2 companies since 2024. The most recent filing shows the insider had shares withheld for taxes covering $1.9K of LGVN on Oct 5, 2026. Across all open-market trades the lifetime net is +$21.0K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $47.0K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OCUP price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 120
FARMINGTON HILLS, MI 48335
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LGVN | Chief Financial Officer | 29,258 | $1.60 | $47.0K | $0 | 2 | 2026-10-05 |
| Opus Genetics, Inc. (OCUP) Delisted | Chief Financial Officer | 194,293 | $1.17 | $227.3K | $21.0K | 4 | 2025-03-17 |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-05 | LGVN | Tax (F) | −742 | -$1.9K | EDGAR |
| 2026-08-25 | LGVN | Grant (A) | +300,000 | $0 | EDGAR |
| 2025-03-17 | Opus Genetics, Inc. (OCUP) Delisted | Grant (A) | +52,500 | $0 | EDGAR |
| 2025-02-18 | Opus Genetics, Inc. (OCUP) Delisted | Tax (F) | −8,207 | -$9.4K | EDGAR |
| 2024-03-25 | Opus Genetics, Inc. (OCUP) Delisted | Buy (P) | +10,000 | $21.0K | EDGAR |
| 2024-02-14 | Opus Genetics, Inc. (OCUP) Delisted | Grant (A) | +140,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.